Literature DB >> 18824294

Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer.

Yao-Kuang Wu1, Kuei-Tien Chen, Yung-Bin Kuo, Ya-Shu Huang, Err-Cheng Chan.   

Abstract

In the present study, pleural effusions are the first time to be used as the specimens for detection of survivin expression in lung cancer patients. We demonstrated that by quantifying survivin expression with enzyme-linked immunosorbent assay (ELISA) in the 80 effusion samples exhibited a diagnostic power of 85% and 75% in sensitivity and specificity, respectively. A multivariate analysis with the Cox regression model revealed that both high survivin expression and cancer cells of stage IV were the indicators for poor prognosis of lung cancer. In conclusion, quantitative assay of survivin in pleural effusion could be useful both in diagnosis and prognosis for lung cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18824294     DOI: 10.1016/j.canlet.2008.08.023

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  Sandwich ELISA for detecting urinary Survivin in bladder cancer.

Authors:  Xuefeng Li; Yaming Wang; Jianjun Xu; Qingyun Zhang
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

Review 2.  Diagnostic value of survivin for malignant pleural effusion: a clinical study and meta-analysis.

Authors:  Panwen Tian; Yongchun Shen; Chun Wan; Ting Yang; Jing An; Qun Yi; Lei Chen; Tao Wang; Ye Wang; Fuqiang Wen
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  Expression of serum survivin protein in diagnosis and prognosis of gallbladder cancer: a comparative study.

Authors:  Jaya Nigam; Abhijit Chandra; Hasan Raza Kazmi; Anshuman Singh; Vishal Gupta; Devendra Parmar; Manoj Kumar Srivastava
Journal:  Med Oncol       Date:  2014-08-17       Impact factor: 3.064

4.  Interferon Regulatory Factor 1 (IRF-1) induces p21(WAF1/CIP1) dependent cell cycle arrest and p21(WAF1/CIP1) independent modulation of survivin in cancer cells.

Authors:  Michaele J Armstrong; Michael T Stang; Ye Liu; Jinbo Gao; Baoguo Ren; Brian S Zuckerbraun; Raja S Mahidhara; Quanhua Xing; Eva Pizzoferrato; John H Yim
Journal:  Cancer Lett       Date:  2011-12-23       Impact factor: 8.679

5.  Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions.

Authors:  Do-Sim Park; Ki-Eun Hwang; Hyeok Shim; Byoung-Ryun Kim; Keum-Ha Choi; Seong-Hoon Park; Seok-Don Park; Eun-Taik Jeong; Hak-Ryul Kim
Journal:  Clin Exp Metastasis       Date:  2011-11-02       Impact factor: 5.150

6.  Evaluation of pleural fluid survivin and XIAP for the diagnosis of malignant pleural effusion.

Authors:  Jian Li; Zhen-Nan Li; Qian-Lei Bao; Li-Ping Ge; Xiao-Qin Li; Ping Chen
Journal:  Tumour Biol       Date:  2012-06-14

7.  Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness.

Authors:  Giueng-Chueng Wang; Po-Shiuan Hsieh; Hsian-He Hsu; Guang-Huan Sun; Shin Nieh; Cheng-Ping Yu; Jong-Shiaw Jin
Journal:  World J Urol       Date:  2009-02-15       Impact factor: 4.226

8.  Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.

Authors:  Yao-Kuang Wu; Chun-Yao Huang; Mei-Chen Yang; Chou-Chin Lan; Chih-Hsin Lee; Err-Cheng Chan; Kuei-Tien Chen
Journal:  Med Oncol       Date:  2014-06-25       Impact factor: 3.064

Review 9.  Monitoring survivin expression in cancer: implications for prognosis and therapy.

Authors:  Rodrigo Santa Cruz Guindalini; Maria Cecília Mathias Machado; Bernardo Garicochea
Journal:  Mol Diagn Ther       Date:  2013-12       Impact factor: 4.074

10.  Combination of long noncoding RNA MALAT1 and carcinoembryonic antigen for the diagnosis of malignant pleural effusion caused by lung cancer.

Authors:  Wan-Wei Wang; Xi-Lei Zhou; Ying-Jian Song; Chang-Hua Yu; Wei-Guo Zhu; Yu-Suo Tong
Journal:  Onco Targets Ther       Date:  2018-04-24       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.